-
1
-
-
84858702540
-
The worldwide epidemiology of type 2 diabetes mellitus: present and future perspectives
-
Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus: present and future perspectives. Nat Rev Endocrinol 2012;8:228-36.
-
(2012)
Nat Rev Endocrinol
, vol.8
, pp. 228-236
-
-
Chen, L.1
Magliano, D.J.2
Zimmet, P.Z.3
-
2
-
-
77953037470
-
Diabetes type 2 pandemic in 21st century
-
Ginter E, Simko V. Diabetes type 2 pandemic in 21st century. Bratisl Lek Listy 2010;111:134-7.
-
(2010)
Bratisl Lek Listy
, vol.111
, pp. 134-137
-
-
Ginter, E.1
Simko, V.2
-
3
-
-
34247483998
-
Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study
-
Fox CS, Coady S, Sorlie PD, D'Agostino RB Sr, Pencina MJ, Vasan RS, Meigs JB, Levy D, Savage PJ. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007;115:1544-50.
-
(2007)
Circulation
, vol.115
, pp. 1544-1550
-
-
Fox, C.S.1
Coady, S.2
Sorlie, P.D.3
D'Agostino Sr., R.B.4
Pencina, M.J.5
Vasan, R.S.6
Meigs, J.B.7
Levy, D.8
Savage, P.J.9
-
4
-
-
0032511583
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
-
UK Prospective Diabetes Study (UKPDS) Group
-
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-53.
-
(1998)
Lancet
, vol.352
, pp. 837-853
-
-
-
5
-
-
77957742069
-
Severe hypoglycemia and risks of vascular events and death
-
ADVANCE Collaborative Group
-
Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-8.
-
(2010)
N Engl J Med
, vol.363
, pp. 1410-1418
-
-
Zoungas, S.1
Patel, A.2
Chalmers, J.3
de Galan, B.E.4
Li, Q.5
Billot, L.6
Woodward, M.7
Ninomiya, T.8
Neal, B.9
MacMahon, S.10
Grobbee, D.E.11
Kengne, A.P.12
Marre, M.13
Heller, S.14
-
6
-
-
45149133036
-
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
-
ADVANCE Collaborative Group.
-
ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
-
(2008)
N Engl J Med
, vol.358
, pp. 2560-2572
-
-
Patel, A.1
MacMahon, S.2
Chalmers, J.3
Neal, B.4
Billot, L.5
Woodward, M.6
Marre, M.7
Cooper, M.8
Glasziou, P.9
Grobbee, D.10
Hamet, P.11
Harrap, S.12
Heller, S.13
Liu, L.14
Mancia, G.15
Mogensen, C.E.16
Pan, C.17
Poulter, N.18
Rodgers, A.19
Williams, B.20
Bompoint, S.21
de Galan, B.E.22
Joshi, R.23
Travert, F.24
more..
-
7
-
-
79952273819
-
Long-term effects of intensive glucose lowering on cardiovascular outcomes
-
ACCORD Study Group
-
ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-28.
-
(2011)
N Engl J Med
, vol.364
, pp. 818-828
-
-
Gerstein, H.C.1
Miller, M.E.2
Genuth, S.3
Ismail-Beigi, F.4
Buse, J.B.5
Goff Jr., D.C.6
Probstfield, J.L.7
Cushman, W.C.8
Ginsberg, H.N.9
Bigger, J.T.10
Grimm Jr., R.H.11
Byington, R.P.12
Rosenberg, Y.D.13
Friedewald, W.T.14
-
8
-
-
79954508355
-
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
-
Barzilai N, Guo H, Mahoney EM, Caporossi S, Golm GT, Langdon RB, Williams-Herman D, Kaufman KD, Amatruda JM, Goldstein BJ, Steinberg H. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011;27:1049-58.
-
(2011)
Curr Med Res Opin
, vol.27
, pp. 1049-1058
-
-
Barzilai, N.1
Guo, H.2
Mahoney, E.M.3
Caporossi, S.4
Golm, G.T.5
Langdon, R.B.6
Williams-Herman, D.7
Kaufman, K.D.8
Amatruda, J.M.9
Goldstein, B.J.10
Steinberg, H.11
-
9
-
-
77953627761
-
Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus
-
Iwamoto Y, Taniguchi T, Nonaka K, Okamoto T, Okuyama K, Arjona Ferreira JC, Amatruda J. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 2010;57:383-94.
-
(2010)
Endocr J
, vol.57
, pp. 383-394
-
-
Iwamoto, Y.1
Taniguchi, T.2
Nonaka, K.3
Okamoto, T.4
Okuyama, K.5
Arjona Ferreira, J.C.6
Amatruda, J.7
-
10
-
-
84859031324
-
Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus
-
Kim SA, Shim WH, Lee EH, Lee YM, Beom SH, Kim ES, Yoo JS, Nam JS, Cho MH, Park JS, Ahn CW, Kim KR. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus. Diabetes Metab J 2011;35:159-65.
-
(2011)
Diabetes Metab J
, vol.35
, pp. 159-165
-
-
Kim, S.A.1
Shim, W.H.2
Lee, E.H.3
Lee, Y.M.4
Beom, S.H.5
Kim, E.S.6
Yoo, J.S.7
Nam, J.S.8
Cho, M.H.9
Park, J.S.10
Ahn, C.W.11
Kim, K.R.12
-
11
-
-
77958540127
-
Vildagliptin: a review of its use in type 2 diabetes mellitus
-
Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2010;70:2089-112.
-
(2010)
Drugs
, vol.70
, pp. 2089-2112
-
-
Keating, G.M.1
-
12
-
-
54249106294
-
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea
-
Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjornsdottir S, Camisasca RP, Couturier A, Baron MA. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008;10: 1047-56.
-
(2008)
Diabetes Obes Metab
, vol.10
, pp. 1047-1056
-
-
Garber, A.J.1
Foley, J.E.2
Banerji, M.A.3
Ebeling, P.4
Gudbjornsdottir, S.5
Camisasca, R.P.6
Couturier, A.7
Baron, M.A.8
-
13
-
-
28844482322
-
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses
-
Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-88.
-
(2005)
Clin Pharmacol Ther
, vol.78
, pp. 675-688
-
-
Herman, G.A.1
Stevens, C.2
Van Dyck, K.3
Bergman, A.4
Yi, B.5
De Smet, M.6
Snyder, K.7
Hilliard, D.8
Tanen, M.9
Tanaka, W.10
Wang, A.Q.11
Zeng, W.12
Musson, D.13
Winchell, G.14
Davies, M.J.15
Ramael, S.16
Gottesdiener, K.M.17
Wagner, J.A.18
-
14
-
-
84863436536
-
Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors
-
Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012;51:501-14.
-
(2012)
Clin Pharmacokinet
, vol.51
, pp. 501-514
-
-
Golightly, L.K.1
Drayna, C.C.2
McDermott, M.T.3
-
15
-
-
84863115894
-
Clinical pharmacokinetics and pharmacodynamics of vildagliptin
-
He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet 2012;51:147-62.
-
(2012)
Clin Pharmacokinet
, vol.51
, pp. 147-162
-
-
He, Y.L.1
-
16
-
-
34347393269
-
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
-
He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, Holst JJ, Schwartz S, Nielsen JC, Ligueros-Saylan M. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007; 46:577-88.
-
(2007)
Clin Pharmacokinet
, vol.46
, pp. 577-588
-
-
He, Y.L.1
Serra, D.2
Wang, Y.3
Campestrini, J.4
Riviere, G.J.5
Deacon, C.F.6
Holst, J.J.7
Schwartz, S.8
Nielsen, J.C.9
Ligueros-Saylan, M.10
-
17
-
-
84866645242
-
Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition
-
Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-82.
-
(2012)
Diabetes Care
, vol.35
, pp. 2076-2082
-
-
Rizzo, M.R.1
Barbieri, M.2
Marfella, R.3
Paolisso, G.4
-
18
-
-
84875054251
-
Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors
-
Barbieri M, Rizzo MR, Marfella R, Boccardi V, Esposito A, Pansini A, Paolisso G. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 2013;227:349-54.
-
(2013)
Atherosclerosis
, vol.227
, pp. 349-354
-
-
Barbieri, M.1
Rizzo, M.R.2
Marfella, R.3
Boccardi, V.4
Esposito, A.5
Pansini, A.6
Paolisso, G.7
-
19
-
-
77952316298
-
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients
-
Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010;59:887-95.
-
(2010)
Metabolism
, vol.59
, pp. 887-895
-
-
Derosa, G.1
Maffioli, P.2
Salvadeo, S.A.3
Ferrari, I.4
Ragonesi, P.D.5
Querci, F.6
Franzetti, I.G.7
Gadaleta, G.8
Ciccarelli, L.9
Piccinni, M.N.10
D'Angelo, A.11
Cicero, A.F.12
-
20
-
-
33846817233
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
-
Sitagliptin Study 024 Group
-
Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205.
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 194-205
-
-
Nauck, M.A.1
Meininger, G.2
Sheng, D.3
Terranella, L.4
Stein, P.P.5
-
21
-
-
33845476757
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
-
Sitagliptin Study 020 Group
-
Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43.
-
(2006)
Diabetes Care
, vol.29
, pp. 2638-2643
-
-
Charbonnel, B.1
Karasik, A.2
Liu, J.3
Wu, M.4
Meininger, G.5
-
23
-
-
84859174317
-
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis
-
Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369.
-
(2012)
BMJ
, vol.344
-
-
Karagiannis, T.1
Paschos, P.2
Paletas, K.3
Matthews, D.R.4
Tsapas, A.5
-
24
-
-
84873873967
-
Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus
-
Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:252-7.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 252-257
-
-
Kothny, W.1
Foley, J.2
Kozlovski, P.3
Shao, Q.4
Gallwitz, B.5
Lukashevich, V.6
-
25
-
-
84875370840
-
Efficacy of vildagliptin on glucose fluctuation in Japanese type 2 diabetic patients with ongoing sulfonylurea based oral glycemic agent therapy
-
Yoshioka K, Isotani H, Ohashi S, Imamura M. Efficacy of vildagliptin on glucose fluctuation in Japanese type 2 diabetic patients with ongoing sulfonylurea based oral glycemic agent therapy. Diabetes Metab Syndr 2013;7:32-4.
-
(2013)
Diabetes Metab Syndr
, vol.7
, pp. 32-34
-
-
Yoshioka, K.1
Isotani, H.2
Ohashi, S.3
Imamura, M.4
-
26
-
-
84879996784
-
Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes
-
Oh TJ, Jung HS, Bae JH, Kim YG, Park KS, Cho YM, Park KS, Kim SY. Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes. J Korean Med Sci 2013;28:881-7.
-
(2013)
J Korean Med Sci
, vol.28
, pp. 881-887
-
-
Oh, T.J.1
Jung, H.S.2
Bae, J.H.3
Kim, Y.G.4
Park, K.S.5
Cho, Y.M.6
Park, K.S.7
Kim, S.Y.8
-
27
-
-
77957740531
-
Clinical impact of glycated albumin as another glycemic control marker
-
Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr J 2010;57:751-62.
-
(2010)
Endocr J
, vol.57
, pp. 751-762
-
-
Koga, M.1
Kasayama, S.2
-
28
-
-
84864619348
-
The roles of glycated albumin as intermediate glycation index and pathogenic protein.
-
Kim KJ, Lee BW. The roles of glycated albumin as intermediate glycation index and pathogenic protein. Diabetes Metab J 2012; 36:98-107.
-
Diabetes Metab J 2012
, vol.36
, pp. 98-107
-
-
Kim, K.J.1
Lee, B.W.2
-
29
-
-
84866674568
-
Glycated albumin is superior to hemoglobin A1c for evaluating the presence and severity of coronary artery disease in type 2 diabetic patients
-
Shen Y, Pu LJ, Lu L, Zhang Q, Zhang RY, Shen WF. Glycated albumin is superior to hemoglobin A1c for evaluating the presence and severity of coronary artery disease in type 2 diabetic patients. Cardiology 2012;123:84-90.
-
(2012)
Cardiology
, vol.123
, pp. 84-90
-
-
Shen, Y.1
Pu, L.J.2
Lu, L.3
Zhang, Q.4
Zhang, R.Y.5
Shen, W.F.6
-
30
-
-
80051553874
-
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials
-
Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. Clin Drug Investig 2011;31:665-74.
-
(2011)
Clin Drug Investig
, vol.31
, pp. 665-674
-
-
Signorovitch, J.E.1
Wu, E.Q.2
Swallow, E.3
Kantor, E.4
Fan, L.5
Gruenberger, J.B.6
-
31
-
-
84864516417
-
Comparison of vildagliptin twice daily vs
-
Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol 2012;11:92.
-
(2012)
sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol
, vol.11
, pp. 92
-
-
Sakamoto, M.1
Nishimura, R.2
Irako, T.3
Tsujino, D.4
Ando, K.5
Utsunomiya, K.6
-
32
-
-
84863705544
-
Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study
-
Lim S, An JH, Shin H, Khang AR, Lee Y, Ahn HY, Yoon JW, Kang SM, Choi SH, Cho YM, Park KS, Jang HC. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. Clin Endocrinol (Oxf) 2012;77:215-23.
-
(2012)
Clin Endocrinol (Oxf)
, vol.77
, pp. 215-223
-
-
Lim, S.1
An, J.H.2
Shin, H.3
Khang, A.R.4
Lee, Y.5
Ahn, H.Y.6
Yoon, J.W.7
Kang, S.M.8
Choi, S.H.9
Cho, Y.M.10
Park, K.S.11
Jang, H.C.12
-
33
-
-
84857903646
-
DPP-4 inhibitors and lipids: systematic review and meta-analysis
-
Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 2012;29:14-25.
-
(2012)
Adv Ther
, vol.29
, pp. 14-25
-
-
Monami, M.1
Lamanna, C.2
Desideri, C.M.3
Mannucci, E.4
|